Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan-based dual vs triple therapy for Helicobacter pylori eradication in high clarithromycin resistance area
TCTR20191219003Phase 1Active, not recruiting
- Sponsor
- N/A
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of vonoprazan in Helicobacter pylori infection (2 arms), sponsored by N/A. Primary endpoint: Helicobacter pylori eradication rate. Started Nov 2019; status: active, not recruiting.
02
Drugs
vonoprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on TCTR20191219003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20191219003.